Merck Nears $6 Billion Acquisition of Terns Pharma to Boost Cancer Portfolio

Merck is reportedly nearing a $6 billion acquisition of Terns Pharma to boost its cancer portfolio, according to a report from the Financial Times ^[7]. The deal, which is expected to be an all-cash transaction, would be one of the largest acquisitions in the pharmaceutical industry in recent years.

The acquisition is seen as a strategic move by Merck to expand its presence in the cancer treatment market, which is expected to grow significantly in the coming years. Terns Pharma has developed several promising cancer treatments, including a new class of immunotherapies that have shown promising results in clinical trials.

The deal is still in the final stages of negotiation, and it is unclear when the acquisition is expected to be completed. However, if the deal is successful, it would be a major coup for Merck, which has been looking to expand its presence in the cancer treatment market.

The acquisition would also be a significant boost to Terns Pharma, which has been working to develop its cancer treatments for several years. The company has received significant funding from investors, including a $100 million Series B funding round in 2025.

The deal is expected to be completed in the coming months, and it is unclear what the terms of the deal will be. However, it is expected that Merck will pay a significant premium for Terns Pharma, given the company's promising pipeline of cancer treatments.

The acquisition is seen as a strategic move by Merck to expand its presence in the cancer treatment market, which is expected to grow significantly in the coming years. The deal would be one of the largest acquisitions in the pharmaceutical industry in recent years, and it would be a major coup for Merck.

Sources

[7] Merck nears $6 billion acquisition of Terns Pharma to boost cancer portfolio, FT reports